Prof. Hermann Luebbert, PhD, serves as the Chief Executive Officer for Biofrontera, Inc. He studied biology in his native city of Cologne, where he completed a PhD in 1984.
After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he was awarded the habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich. Prof. Lübbert has held the Chair of Animal Physiology at Ruhr-University Bochum since 1998. During his ten years at Sandoz and Novartis Pharma AG, Prof. Lübbert acquired experience in managing a globally active research organisation.
In 1997, he founded the German Biofrontera AG, which he headed as CEO until December 2021.
Fred Leffler serves as the Chief Financial Officer for Biofrontera Inc., joining Biofrontera in 2022. Fred is an experienced financial executive with 15 years of leadership, financial management, consultancy, operations, and analytics experience across a range of private and public organizations, including growth-stage, private equity, and Fortune 100 companies. Prior to joining Biofrontera, Fred was a consultant at McKinsey & Co. and FTI Consulting, advising clients in corporate finance, strategy, public company readiness, and analytics in the healthcare, private equity, real estate, and manufacturing industries. He also held finance and accounting leadership positions at GE Energy and SunEdison.
Fred received a BSBA in finance and economics from The Ohio State University’s Fisher School of Business and a MBA from Duke University’s Fuqua School of Business.
Mark Baldyga is responsible for the planning and execution of Biofrontera Inc.’s sales and marketing strategy in the US. Mark joined Biofrontera Inc. in May of 2016 as the first employee in the US and was an integral part of the launch of Ameluz . He brings more than 20 years of pharmaceutical and medical device experience to his position with over 13 years focused in the dermatology specialty. Prior to joining Biofrontera, Mark was a Regional Sales Manager with Valeant Pharmaceuticals, where he led a team of specialty territory managers with a robust portfolio of products focused on diseases of the skin. He also spent many years with Stiefel, a GSK company with the primary focus on leading a sales team. He served on multiple advisory boards, launch committees and was a trainer, marketer and peer educator. Investing in people, developing future leaders, and coaching sales people to drive sales results while building their self-esteem, confidence, and a level of engagement is what he loves to do. Mark earned his B.A. from the University of South Carolina.
Alycia Torres serves as Vice President of Administration, responsible for strategic development and oversight the Human Resources, Information Technology, Quality, and Inside Operations functions at Biofrontera, Inc. She has over 15 years of experience in finance, strategy, and operations. Prior to coming to Biofrontera, Alycia worked at Pear Therapeutics, a life science company pioneering the field of prescription digital therapeutics. There she played an integral role in supporting the product development, clinical, and general and administrative functions as the company grew from start-up mode into a publicly traded company. She held progressive roles at Fidelity including corporate decision support and site strategy. Alycia began her career in the audit function at Deloitte & Touche. Alycia earned her BS degree in Accounting from Fairfield University.
Jon Lyons serves as Vice President of Scientific & Medical Affairs, responsible for strategic development and oversight of field medical, medical information & communications, thought leader initiatives, education grants and post-market evidence generation, including investigator-initiated research and real-world data programs at Biofrontera, Inc. Including his cancer research training, Jon brings over 20 years of experience in scientific, medical, and clinical affairs. Prior to Biofrontera, Jon held management roles at Incyte Corp and Providence Medical Technology, where he led teams of MSLs and CRAs, with a focus on launching first-to-market assets in medical dermatology and spinal fusion. He also worked at DUSA Pharmaceuticals and Smith & Nephew Orthopedics. In the past 7 years, Jon has built and coached high-performing teams and has been integral in operationalizing medical science programs at Biofrontera from the department’s inception. Jon earned his PhD in cancer research from MD Anderson Cancer Center in Houston, and his MBA in Biomedical Management from the University of Memphis.
Daniel Hakansson joined Biofrontera Inc. as Corporate Counsel in January 2019. As Corporate Counsel, Dan is responsible for advising Biofrontera Inc.’s leadership team on corporate governance, contracts, compliance, business policy and other various legal matters. He was also appointed as Head of Compliance in November 2019. In this role, Dan leads the oversight, growth, and expansion of Biofrontera’s commercial compliance program. Prior to joining Biofrontera, Dan worked as a litigation attorney at a private law firm where he represented clients in many practice areas and specialized in Employment Law. During his tenure at the firm, Dan was a key member of the legal team who successfully represented a medical device component manufacturer in a highly contentious and precedent setting trade secret defense. He also has experience working with the Hillsborough County Attorney’s Office, the New Hampshire Commission for Human Rights and as a student clerk for a New Hampshire Supreme Court justice. Dan received his Juris Doctorate from the University of New Hampshire School of Law, where he was a member of the Daniel Webster Scholars Honors program. He also received a B.A. in Political Science from the University of Massachusetts – Amherst.
Erica Gates joined Biofrontera Inc. in August 2019 as the Corporate Controller. She is responsible for overseeing all aspects of financial reporting and the related accounting and control strategies and activities. Prior to joining Biofrontera Inc., Erica gained over ten years of progressive experience in both the pharmaceutical and financial services industries after beginning her career in public accounting at Caturano and Company in the audit practice. She brings significant experience in accounting policy, operations and strategy including extensive experience with public company reporting requirements. Most recently, Erica served as the Corporate Accounting Manager at Affiliated Managers Group, Inc. where she was responsible for management of financial accounting and treasury functions within a complex business structure while ensuring compliance with foreign and domestic regulatory requirements. Erica received a M.S. in Accountancy and M.B.A. from Northeastern University and has been a Certified Public Accountant since September 2009.